National Cancer Institute; Amended Notice of Meeting, 4521-4522 [07-401]

Download as PDF Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices are to respond, including the use of appropriate automated electronic, mechanical, or other technological collection techniques or other forms of information technology. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Nancy Breen, Ph.D., Project Officer, Applied Research Program, Division of Cancer Control and Population Sciences NCI, NIH, EPN 4005, 6130 Executive Boulevard MSC 7344. Bethesda, Maryland 20852–7344, or call the nontoll-free number 301–696–8500 or Email your request, including your address to breenn@mail.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. Dated: January 23, 2007. Rachelle Ragland-Greene, NCI Project Clearance Liaison, National Institutes of Health. [FR Doc. 07–406 Filed 1–30–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health mstockstill on PROD1PC62 with NOTICES National Cancer Institute; Call for Nominations for the National Cancer Institute Director’s Consumer Liaison Group The National Cancer Institute (NCI) the Federal Government’s primary agency for cancer research, is seeking nominations for four (4) new members of the NCI Director’s Consumer Liaison Group (DCLG) which will be appointed in July, 2007. The DCLG helps NCI to identify appropriate advocates to serve on its program and policy advisory committees. The National Cancer Institute (NCI) formed the NCI Director’s Consumer Liaison Group (DCLG) in 1998 to advise and make recommendations to the NCI Director, from the perspective and viewpoint of cancer consumer advocates, on a wide variety of issues, programs, and research priorities. The VerDate Aug<31>2005 15:08 Jan 30, 2007 Jkt 211001 DCLG gives cancer advocates a channel to voice their views and concerns. The DCLG is a 16-member chartered federal advisory committee that works with NCI to ensure that those who experience the burden of cancer also help to shape the course of the NCI’s research to eradicate it. Specifically the DCLG members: • Help develop and establish processes, mechanisms and criteria for identifying appropriate consumer advocates to serve on a variety of program and policy advisory committees responsible for advancing the mission of the NCI. • Serve as a primary forum for discussion issues and concerns and exchanging viewpoints that are important to the broad development of the NCI programming and research priorities. • Establish and maintain strong collaborations between the NCI and the cancer advocacy community to reach common goals. Eligibility Requirements: NCI looks for strong, highly qualified candidates who fulfill the following eligibility criteria: • Demonstrate involvement in the cancer experience as a cancer survivor, a caregiver to someone who has cancer, or as a professional or volunteer who works with cancer survivors, patients, or caregivers; • Have a constituency with which she/he regularly communicates on cancer issues and with which she/he is able to serve as a conduit for information, both to and from NCI. Nominees who meet the minimum eligibility requirements will be evaluated further based on the following qualities: • Cancer advocacy experience; ability to represent all cancer survivors; • Possession of strong leadership, communication, and collaboration skills; • Ability to advise on broad cross cutting cancer issues; • Ability to facilitate dialogue between NCI and the cancer advocacy community. DCLG members must be committed to participating in all activities of the DCLG which includes at least two meetings a year in Bethesda, MD. Characteristics of the DCLG. In addition to the criteria for individual candidates, the following characteristics of the DCLG as a group are balanced to ensure that it reflects the breadth and diversity of the consumer advocacy community: • Racial and ethnic balance • A broad mix of cancer sites • Expertise with advocacy organizations (local, regional, or national) PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 4521 • Geographical diversity • Gender • Age diversity Selection Process. A call for nominations is disseminated annually to a broad range of groups, including local, regional and national organizations, to encourage nominations of candidates reflecting the diversity sought for the DCLG. Individuals may nominate themselves. All nominees are screened for eligibility, and then evaluated according to the criteria. A list of highly qualified candidates who reflect balance and diversity of representation is forwarded to the Director, NCI who selects the DCLG members. The original members of the DCLG endorsed this process and the criteria developed to evaluate the applications of potential DCLG members, and this process is used to select future members. To receive a nomination package for the DCLG, send your name, advocacy/ voluntary organization affiliation (if any), address, phone number and E-mail information to: Palladian Partners, Inc., Attn: DCLG 2007 Selection Process, 1010 Wayne Avenue, Suite 1200, Silver Spring, MD 20910, Phone: (301) 650– 8660, Fax: (301) 650–8676. Nominations must be postmarked by March 30, 2007. Dated: January 23, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy, National Institutes of Health. [FR Doc. 07–400 Filed 1–30–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, February 27, 2007, 12 p.m. to February 27, 2007, 4 p.m., National Institutes of Health, 6130 Executive Blvd., Rockville, MD 20852 which was published in the Federal Register on December 28, 2006, 71 FR 78214. The meeting notice is changed to reflect the change in the name of the committee from ‘‘SBIR Topic 230 (Phases I & II)’’ to ‘‘SBIR, Synthesis Stable Isotope-Labeled Steroids as Internal Standards.’’ The meeting is closed to the public. E:\FR\FM\31JAN1.SGM 31JAN1 4522 Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices Dated: January 23, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–401 Filed 1–30–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings mstockstill on PROD1PC62 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Initial Review Group; Subcommittee 1—Career Development. Date: February 27–28, 2007. Time: 8 a.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: The Hilton Alexandria Old Town, 1767 King Street, Alexandria, VA 22314. Contact Person: Robert Bird, PhD, Scientific Review Administrator, Resources and Training Review Branch, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 8113, MSC 8328, Bethesda, MD 20892–8328, 301– 496–7978, birdr@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Innovative Technologies for Molecular Analysis of Cancer. Date: March 7–8, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Sherwood Githens, PhD, Scientific Review Administrator, Special Review and Logistics Branch, National Cancer Institute, Division of Extramural Activities, 6116 Executive Blvd., Room 8053, Bethesda, MD 20892, 301–435–1822, githenss@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, TW06–006 ‘‘International Tobacco and Health Research and Building Capacity.’’ Date: March 20–21, 2007. VerDate Aug<31>2005 15:08 Jan 30, 2007 Jkt 211001 Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard Gaithersburg Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878. Contact Person: Gerald G. Lovinger, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8101, Bethesda, MD 20892–8329, 301–496–7987, lovingeg@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: January 23, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–402 Filed 1–30–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Special Emphasis Panel, February 23, 2007, 8:30 a.m. to February 23, 2007, 3 p.m., Embassy Suites Hotel Washington Convention Ctr., Washington, DC 20001 which was published in the Federal Register on January 12, 2007, FR 07–100. The February 23, 2007 Meeting Panel Name was changed from Modified Hemoglobin Production to VAD Technologies. The meeting is closed to the public. Dated: January 24, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–397 Filed 1–30–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Special Emphasis PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 Panel, February 20, 2007, 2 p.m. to February 20, 2007, 3 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the Federal Register on January 12, 2007, FR 07–100. The February 20, 2007 Meeting Panel Name was changed from VAD Technologies to Modified Hemoglobin Production. The meeting is closed to the public. Dated: January 24, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–398 Filed 1–30–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental & Craniofacial Research; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; 07–43, Review R03, F30. Date: February 12, 2007. Time: 1:30 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Raj K. Krishnaraju, PhD, MS, Scientific Review Administrator, Scientific Review Branch, National Inst. of Dental & Craniofacial Research, National Institutes of Health, 45 Center Dr. Rm 4AN 32J, Bethesda, MD 20892, 301–594–4864, kkrishna@nidcr.nih.gov. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; 07–35, Review R21. Date: March 1, 2007. Time: 11 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\31JAN1.SGM 31JAN1

Agencies

[Federal Register Volume 72, Number 20 (Wednesday, January 31, 2007)]
[Notices]
[Pages 4521-4522]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-401]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Cancer Institute Special Emphasis Panel, February 27, 2007, 12 p.m. to 
February 27, 2007, 4 p.m., National Institutes of Health, 6130 
Executive Blvd., Rockville, MD 20852 which was published in the Federal 
Register on December 28, 2006, 71 FR 78214.
    The meeting notice is changed to reflect the change in the name of 
the committee from ``SBIR Topic 230 (Phases I & II)'' to ``SBIR, 
Synthesis Stable Isotope-Labeled Steroids as Internal Standards.'' The 
meeting is closed to the public.


[[Page 4522]]


    Dated: January 23, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-401 Filed 1-30-07; 8:45 am]
BILLING CODE 4140-01-M